Kyntra Bio

KYNB

Medical - Pharmaceuticals · Healthcare

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Mar 31, 2026

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Data not available

Valuation

Good

Track this stock — start free trial

Winston Score History

The full picture

Kyntra Bio, Inc. does not appear in my training data as a recognized public company. The ticker KYNB and the name Kyntra Bio are not entities I can verify with confidence. Writing specific details about its products, pipeline, or business model would risk presenting invented information as fact.

To generate an accurate description, please provide any of the following: a brief company description, its main drug candidates or therapeutic focus, its stage of development (clinical-stage vs. commercial), and its primary geographic market. With that context, an accurate and balanced two-paragraph summary can be produced.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

-9.8%

Thin — -9.8% gross margin

Profit after running costs

Operating Margin

-369.7%

Losing money on operations — -369.7%

Return on the money invested

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

Data not available

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

-13%

Weak — only -13% of profit becomes cash

Spare cash per sale

FCF Margin

-287.7%

Burning cash (-287.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

0.1x

no trend

Attractive valuation — P/E 0.1

P/E under 10. The price tag is small relative to last year's profit.

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial